PROTEOME SCIENCES PLC

Board/Management Information • Nov 25, 2025

National Storage Mechanism | Additional information

RNS Number : 8031I

Proteome Sciences PLC

25 November 2025

25 November 2025

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Nominated Adviser and Broker

Proteome Sciences (AIM:PRM), is pleased to announce that SP Angel Corporate Finance LLP has been appointed as the Company's new Nominated Adviser and sole Broker with immediate effect.

Christopher Pearce, Executive Chairman commented that:  'We are delighted to have the opportunity to work closely with the team at SP Angel and look forward to their support as we further develop Proteome Sciences.'

For further information:

Proteome Sciences plc
Christopher Pearce, Executive Chairman
Dr. Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer	Tel: +44 (0)20 7043 2116
SP Angel Corporate Finance LLP (Nominated Adviser & Broker)
David Hignell / Richard Morrison / Josh Ray (Corporate Finance)
Vadim Alexandre (Corporate Broking)	Tel: +44 (0)20 3470 0470

AIM Rule 17 Disclosures

In accordance with AIM Rule 17 and Schedule Two (g) sub-paragraph (v) of the AIM Rules for Companies, the Company confirms that between 2001 and 2015 Roger McDowell, Non-Executive Director, was a director or partner of the following companies at the time of, or in the 12 months preceding, such company entering administration or liquidation proceedings:

-      Town Index Limited - Creditors Voluntary Liquidation in January 2001, and subsequently dissolved in 2005;

-   Wax Digital Limited (subsequently Onward Digital Ltd) - Creditors Voluntary Liquidation in 2001, and subsequently dissolved in 2015;

-      Advanced Fluid Connections plc - Appointment of Receivers in 2006, and subsequently dissolved in 2009;

-      IDMoS plc - Appointment of Administrators in April 2008 (with Administration in May 2008), and subsequently dissolved in 2009; and

-      Corsair Techinvest Ltd - Members Voluntary Solvent Liquidation in 2015.

- Ends -

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPBIBRTMTJTBFA